Historic Partnership between the Weizmann Institute of Science and Institut Curie
25.3.2019 19:54:00 EET | Business Wire | Press release
On March 22, the Weizmann Institute of Science in Rehovot, Israel, and Institut Curie in Paris, France, two major world-class research institutes, signed an historic partnership that will allow their teams to work closely together to improve knowledge in the field of life sciences, particularly in the areas of physics and chemistry, and most specifically - in the field of cancer research. This is a milestone in the history of these two institutes that have been working together for 15 years, particularly in the field of biophysics.
Collaborative research programs
This partnership will extend to many disciplines, including physics,
chemistry, cellular biology, epigenetics, genetics, immunology and
single cell approaches, imagery and data collection. The complementarity
of the research between the various groups at Institut Curie and at the
Weizmann Institute has been recognized in particular at the occasion of
joint scientific workshops held regularly alternatively in Paris and
Rehovot. Each research program will be organized around a pair of
researchers with a scientist from Institut Curie and a scientist from
the Weizmann Institute of Sciences, who will receive support on the
annual basis. This partnership also includes exchanges of scientists and
a Curie-Weizmann symposium organized every two years, with alternate
locations in Rehovot, Israel, and in Paris, which will be focused on one
of the subjects of research cooperation.
To finance the start of
this cooperation, Institut Curie and the Weizmann Institute of Sciences
will finance this research program for €200,000 each, and will organize
a joint fundraiser with philanthropists and corporate sponsors.
Projects with high hopes
There are numerous common interests
between the two Institutes. They can range from the description of
defects in cell nuclei to the mechanics of cell migration, or the
behavior of neural networks. A few examples of exciting ongoing projects
are highlighted below.
During his sabbatical visit at Institut
Curie in 2012, Professor Nir Gov (Weizmann Institute) participated in
several projects ranging from cell migration to collective cell
behaviors and neuron growth. For instance, he developed a theory in
collaboration with Raphael Voituriez (Sorbonne University), which
explains the observations of the team of Matthieu Piel (Institut Curie)
on the links between persistence and speed of migrating cells. This
theory gave rise to collaborative developments between these three teams
to predict important aspects of the migratory behavior of immune cells.
He
also collaborated with Pascal Silberzan at Institut Curie to understand
the behavior of cells packed at very high density on a surface. This
joint work combining experiments and theory, has highlighted the
importance of an intrinsic biological ageing of the cell population.
This project has helped understanding how cells can come to an arrest
while maintaining a capacity to respond to external perturbations such
as an injury.
Elisha Moses (Weizmann Institute) has a longstanding
interaction with the group of Professor Jean-Louis Viovy (Institut
Curie), now headed by Stéphanie Descroix, on the applications of
microfluidic devices to the study of living neuronal networks. He spent
three months in Paris, during which he and Dr. Catherine Villard of the
Descroix lab developed an optogenetic assay for guiding axonal growth.
This work has the potential for controlling growth of neurons and of
neuronal tumors within the brain. Drs. M. Vignes and R. Renault, two
talented researchers who were working on the project as students, have
now graduated and branched off into very interesting conceptual and
practical applications of this approach.
An important complementarity
The two institutions are both
highly complementary and display many mutually common attributes.
Institut
Curie is the premier research center in France conducting cancer
research, including all facets of carcinogenesis. Its research center
brings together 1,200 researchers working in 12 joint research units
organized in four areas based on natural scientific interactions and
robust medical potentiality. A strong advocate of international
cooperation , it welcomes more than 80 nationalities. Equipped with
advanced technology platforms, it is an important resource for
researchers around the world. Institut Curie is also a state-of-the-art
hospital complex that provides care and support for all cancer types and
welcomes more than 50,000 patients each year. It has developed
particularly innovative treatments directly from the work of its
research center. Institut Curie also trains students in science and
cancer research with the goal of increasing the knowledge about the
topic.
The Weizmann Institute of Science is among the ten premier
institutes of fundamental research in the world: 2,500 scientists work
on its campus in Rehovot in the complementary fields of mathematics and
computer science, physics, biology, chemistry, and biochemistry. The
Weizmann Institute of Science has a long history of research and
discoveries rooted in a mission of advancement of science for the
benefit of humanity; cancer research accounts for 40% of the total
budget of the Institute, which shapes and hosts a large part of the
leadership in Israel and contributes to the advancement and
understanding of scientific issues among all audiences.
Both
institutions have powerful means of technology transfer that leverage
the discoveries of their labs for the benefit of patients, whether
through the creation of medications, medical devices or other
technologies.
A shared vision of science
Science at the service of people
- this is the best way to describe the credo of the two institutes, both
of which were founded upon great personalities who have made an
important mark in the history of the world.
Chaim Weizmann, chemist
and author of many discoveries and publications, is the founder of the
Weizmann Institute, and was the first president of the State of Israel
between 1949 and 1952. Marie Curie, born Maria Sklodowska, founded the
Radium Institute in 1909. The first female professor and holder of a
chair position at the Sorbonne, the first woman to win two Nobel prizes
and be enshrined at the Pantheon in Paris on her own merit. In many
ways, these two scientists have had a remarkable journey.
But
beyond these prestigious founders, the two institutes share the same
vision of science, at the service of people and driven by strong values,
the same curiosity for discovery and knowledge at the service of human
health.
The
Weizmann Institute of Science and Institut Curie also share a common
belief that international collaborations in the field of institut-curie.org
science and the exchange of ideas across interdisciplinary boundaries
can accelerate progress to the benefit of humanity.
It is this
common ground which today enables this collaboration to take root and
which will tomorrow allow us to multiply efforts and as a result enjoy
major new discoveries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190325005638/en/
Contact information
Yohan Philippe
yohan.philippe@curie.fr
+33
(0)1 56 24 55 53
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Special Olympics Airlift Takes Flight Nationwide; Dove 1 Arrives at St. Paul Downtown Airport19.6.2026 18:09:00 EEST | Press release
The 2026 Special Olympics Airlift officially took flight today as all participating Cessna, Beechcraft and Hawker aircraft, known as Doves, departed from airports across the country. Dove 1 for arrival day, a Cessna Citation Latitude generously operated by Prent Corporation, landed at St. Paul Downtown Airport (STP) carrying Special Olympic athletes and delegation members, signaling the start of Airlift arrivals for the Special Olympics USA Games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619085293/en/ Special Olympics Airlift takes flight nationwide; Dove 1 arrives at St. Paul Downtown Airport (Photo credit: Textron Aviation). The arrival signals the start of the world’s largest cumulative peacetime airlift spanning more than 40 years, a coordinated aviation effort organized by Textron Aviation, a Textron Inc. (NYSE: TXT) company, that transports hundreds of Special Olympics athletes and coaches from multiple states
Record Currency Management Participates in Innovative European Bank for Reconstruction and Development (EBRD) -Backed Mongolian Tugrik Transaction19.6.2026 17:53:00 EEST | Press release
Record Currency Management Ltd (RCM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce its participation in an innovative local currency bond transaction issued by the European Bank for Reconstruction and Development (EBRD), supporting the development of Mongolia's capital markets while providing institutional investors with access to attractive frontier market opportunities. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The investment forms part of Record Financial Group's broad
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
